Patient P-01383
Therapy response
Unstable
Tolerance
Deteriorating
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Declining
Discontinuation risk
64%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 GI symptom burden −28% vs expected — Dietary Support Protocol NP-02
- Day 46 SC-12 recommended — Supportive Compound SC-12
- Day 47 Patient accepted — Started SC-12 in the companion
- Day 48 Tolerance state changed — Unstable → Improving
- Day 53 GI symptom burden −21% vs expected — Supportive Compound SC-12
- Day 54 GI-04 recommended — GI Support Protocol GI-04
- Day 55 Patient accepted — Started GI-04 in the companion
- Day 58 ME-01 recommended — Monitoring Escalation ME-01
- Day 59 Tolerance state changed — Unstable → Improving
- Day 59 Patient accepted — Started ME-01 in the companion
- Day 62 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
- Day 63 GI symptom burden −23% vs expected — GI Support Protocol GI-04
- Day 69 Tolerance state changed — Unstable → Improving
- Day 112 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 112.
Primary contributors, last 14 days
- Nutritional resilience-12
- GI instability+10
- Toxicity+9
- Inflammatory activity+8
- Treatment adherence+2
What helped?
- Dietary Support Protocol NP-02Day 31Result: symptom burden −28%
- Supportive Compound SC-12Day 46Result: symptom burden −21%
- GI Support Protocol GI-04Day 54Result: symptom burden −23%
- Monitoring Escalation ME-01Day 58Result: deterioration detected before clinical escalation
LIFE OS recommendation
Clinician Review CR-01
81%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 5 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↑70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 41
- Butyrate / short-chain fatty acid production ↓60
- MicrobiomeButyrate capacity 25/100
- MicrobiomeF. prausnitzii depleted
- Autonomic recovery ↓25
- WearableResting HR 79 bpm
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Rapid metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.9 · butyrate capacity 25/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 50 ms
- Sleep
- 6.7 h
- Steps
- 3,406
- Resting HR
- 79 bpm
Daily log: GI score 39, nutritional resilience 52, adherence 62.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01688 | 40% | S01 | GI-04 | improved | 40 |
| P-01327 | 31% | S01 | GI-04 | improved | 56 |
| P-01846 | 31% | S01 | — | — | 37 |
| P-01823 | 30% | S01 | — | — | 57 |
| P-01310 | 29% | S01 | — | — | 57 |
| P-01731 | 29% | S01 | ME-01 | improved | 32 |
| P-01816 | 29% | S01 | — | — | 35 |
| P-01604 | 28% | S01 | — | — | 71 |
| P-01821 | 28% | S01 | — | — | 58 |
| P-01313 | 27% | S01 | BR-03 | improved | 32 |
| P-01635 | 41% | S02 | GI-04 | improved | 49 |
| P-01452 | 33% | S02 | GI-04 | improved | 46 |